U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07523100) titled 'A Study on the Safety and Tolerability of Universal STAR-T Cell Therapy for Multiple Sclerosis.' on April 04.
Brief Summary: This is a Phase I, single-arm, open-label, dose-escalation and dose-expansion study.
The main objective is to explore the safety and tolerability of the universal STAR-T cell injection in patients with progressive or relapsing-remitting multiple sclerosis (MS).The secondary objectives are to evaluate the efficacy of the universal STAR-T cell injection in treating patients with progressive or relapsing-remitting MS; and to assess the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the univers...